Discovery Hub
Human signal regulatory protein alpha (SIRP alpha variant V2 extracellular D1 domain, SIRP alpha V2D1) fragment 31-163, comprising the first two extracellular loops of the D1 domain, [N110>A80]-variant, anti-(human CD47, integrin associated protein (IAP)) (1-133 in the current sequence) fused via a (G4S) 2 peptide linker (134-143) to gamma 1 heavy chain (144-594) [VH (Mus musculus IGHV1-12*01 -(IGHD) -IGHJ1*01, CDR-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo sapiens IGHG1*03(CH1 (265-362), hinge (363-377), CH2 S445>A, E480>A, K 481>A (378-487), CH3 (488-592), CHS (593-594)) (265-594)], (367-213')-disulfide with kappa light chain (1'-213') [V-KAPPA (Mus musculus IGKV4-72*01 -IGKJ1*01, CDR-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dimer (373-373'':376-376'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

Human signal regulatory protein alpha (SIRP alpha variant V2 extracellular D1 domain, SIRP alpha V2D1) fragment 31-163, comprising the first two extracellular loops of the D1 domain, [N110>A80]-variant, anti-(human CD47, integrin associated protein (IAP)) (1-133 in the current sequence) fused via a (G4S) 2 peptide linker (134-143) to gamma 1 heavy chain (144-594) [VH (Mus musculus IGHV1-1201 -(IGHD) -IGHJ101, CDR-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo sapiens IGHG103(CH1 (265-362), hinge (363-377), CH2 S445>A, E480>A, K 481>A (378-487), CH3 (488-592), CHS (593-594)) (265-594)], (367-213')-disulfide with kappa light chain (1'-213') [V-KAPPA (Mus musculus IGKV4-7201 -IGKJ101, CDR-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo sapiens IGKC01 (107'-213')]; dimer (373-373'':376-376'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

B-cell Non-Hodgkin's Lymphoma

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.monoclonal_antibodyPhase 1/2Active

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 40/ 100
Competitive Position: 89/ 100

Competitive context

316 Active assets in the B-cell Non-Hodgkin's Lymphoma cohort.

Asset / Sponsor	Phase	Rating
VINDESINE Children's Cancer Group, China	Phase 4	BBB
cc-5013 Shanghai Junshi Bioscience Co., Ltd.	Phase 4	BBB
Odronextamab University of Birmingham	Phase 3	BBB
Cytosin-Arabinosid Children's Cancer Group, China	Phase 4	BBB
METHOTREXATE Children's Cancer Group, China	Phase 4	BBB

View all 50 →

Same molecule, other indications

Human signal regulatory protein alpha (SIRP alpha variant V2 extracellular D1 domain, SIRP alpha V2D1) fragment 31-163, comprising the first two extracellular loops of the D1 domain, [N110>A80]-variant, anti-(human CD47, integrin associated protein (IAP)) (1-133 in the current sequence) fused via a (G4S) 2 peptide linker (134-143) to gamma 1 heavy chain (144-594) [VH (Mus musculus IGHV1-12*01 -(IGHD) -IGHJ1*01, CDR-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo sapiens IGHG1*03(CH1 (265-362), hinge (363-377), CH2 S445>A, E480>A, K 481>A (378-487), CH3 (488-592), CHS (593-594)) (265-594)], (367-213')-disulfide with kappa light chain (1'-213') [V-KAPPA (Mus musculus IGKV4-72*01 -IGKJ1*01, CDR-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dimer (373-373'':376-376'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa is also rated in:

follicular lymphomaDormant

Indicative ·

60 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →